Pharmaceutical firms ‘underinvest’ in long-term research to develop new cancer-fighting drugs due to the greater time and cost required to conduct such research, according to a newly published study.
Pharmaceutical firms ‘underinvest’ in long-term research to develop new cancer-fighting drugs due to the greater time and cost required to conduct such research, according to a newly published study.
